Nutrition, Metabolism & Cardiovascular Diseases
Volume 19, Issue 8 , Pages 580-586 , October 2009

Higher HDL cholesterol levels are associated with a lower incidence of chronic kidney disease in patients with type 2 diabetes

  • G. Zoppini

      Affiliations

    • Section of Endocrinology, Department of Biomedical and Surgical Sciences, University of Verona, Ospedale Civile Maggiore, Piazzale Stefani, 1, 37126 Verona, Italy
    • These authors contributed equally to this work.
    • ,
  • G. Targher

      Affiliations

    • Section of Endocrinology, Department of Biomedical and Surgical Sciences, University of Verona, Ospedale Civile Maggiore, Piazzale Stefani, 1, 37126 Verona, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 045 8123748; fax: +39 045 8027314.
    • These authors contributed equally to this work.
    • ,
  • M. Chonchol

      Affiliations

    • Division of Renal Diseases and Hypertension, University of Colorado Health Sciences Center, Denver, USA
    • ,
  • F. Perrone

      Affiliations

    • Section of Endocrinology, Department of Biomedical and Surgical Sciences, University of Verona, Ospedale Civile Maggiore, Piazzale Stefani, 1, 37126 Verona, Italy
    • ,
  • G. Lippi

      Affiliations

    • Section of Clinical Chemistry, Department of Biomedical and Morphological Sciences, University of Verona, Verona, Italy
    • ,
  • M. Muggeo

      Affiliations

    • Section of Endocrinology, Department of Biomedical and Surgical Sciences, University of Verona, Ospedale Civile Maggiore, Piazzale Stefani, 1, 37126 Verona, Italy

Received 22 August 2008 ,Revised 17 October 2008 ,Accepted 10 November 2008.

References 

  1. Mogensen CE, Cooper ME. Diabetic renal disease: from recent studies to improved clinical practice. Diabet Med. 2004;21:4–17
  2. Rossing P. Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005. Diabetologia. 2006;49:11–19
  3. Rossing P. Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history. Curr Diab Rep. 2006;6:479–483
  4. Lewis EJ. Treating hypertension in the patient with overt diabetic nephropathy. Semin Nephrol. 2007;27:182–194
  5. Fioretto P, Bruseghin M, Berto I, Gallina P, Manzato E, Mussap M. Renal protection in diabetes: role of glycemic control. J Am Soc Nephrol. 2006;17(4 Suppl. 2):S86–S89
  6. UK Prospective Diabetes Study (UKPDS) Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  7. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–412
  8. Valmadrid CT, Klein R, Moss SE, Klein BEK. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med. 2000;160:1093–1100
  9. Wahba IM, Mak RH. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol. 2007;2:550–562
  10. Dalrymple LS, Kaysen GA. The effects of lipoproteins on the development and progression of renal disease. Am J Nephrol. 2008;28:723–731
  11. Molitch ME, Rupp D, Carnethon M. Higher levels of HDL-C are associated with a decreased likelihood of albuminuria in patients with long-standing type 1 diabetes. Diabetes Care. 2006;29:78–82
  12. Rossi MC, Nicolucci A, Pellegrini F, Comaschi M, Ceriello A, Cucinotta D, et al. Identifying patients with type 2 diabetes at high risk of microalbuminuria: results of the DEMAND (Developing Education on Microalbuminuria for Awareness of renal and cardiovascular risk in Diabetes) Study. Nephrol Dial Transplant. 2008;23:1278–1284
  13. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med. 2006;354:2473–2483
  14. Froissart M, Rossert J, Jacquot C, Paillard M, Houillier P. Predictive performance of the modification of diet in renal disease and Cockcroft–Gault equations for estimating renal function. J Am Soc Nephrol. 2005;16:763–773
  15. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, American Diabetes Association , et al. Nephropathy in diabetes. Diabetes Care. 2004;27(Suppl. 1):S79–S83
  16. No authors listed Grading diabetic retinopathy from stereoscopic color fundus photographs–an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98:786–806
  17. Targher G, Bertolini L, Zenari L, Lippi G, Pichiri I, Zoppini G, et al. Diabetic retinopathy is associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabet Med. 2008;25:45–50
  18. Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Pagano G, et al. Progression to overt nephropathy in type 2 diabetes. The Casale Monferrato Study. Diabetes Care. 2003;26:2150–2155
  19. Parving HH. Diabetic nephropathy: prevention and treatment. Kidney Int. 2001;60:2041–2055
  20. Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med. 1998;158:998–1004
  21. Obermayr RP, Temml C, Knechtelsdorfer M, Gutjahr G, Kletzmayr J, Heiss S, et al. Predictors of new-onset decline in kidney function in a general middle-European population. Nephrol Dial Transplant. 2008;23:1265–1273
  22. Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003;14:2084–2091
  23. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the Atherosclerosis Risk in Communities Study. Kidney Int. 2000;58:293–301
  24. Haroun MK, Jaar BG, Hoffman SC, Comstock GW, Klag MJ, Coresh J. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol. 2003;14:2934–2941
  25. Jafar TH, Schmid CH, Stark PC, Toto R, Remuzzi G, Ruggenenti P, et al. The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis. Nephrol Dial Transplant. 2003;18:2047–2053
  26. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17:2006–2016
  27. Strippoli GFM, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomized controlled trials. BMJ. 2008;336:645–651
  28. Movva R, Rader DJ. Laboratory assessment of HDL heterogeneity and function. Clin Chem. 2008;54:1–13
  29. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res. 2005;96:1221–1232
  30. Meyers CD, Kashyap ML. Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protection. Curr Opin Cardiol. 2004;19:366–373
  31. Metascreen Writing Committee , Bonadonna RC, Cucinotta D, Fedele D, Riccardi G, Tiengo A. The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey. Diabetes Care. 2006;29:2701–2707
  32. Avogaro A, Giorda C, Maggini M, Diabetes and Informatics Study Group , Association of Clinical Diabetologists , Istituto Superiore di Sanità , et al. Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care. 2007;30:1241–1247
  33. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M, et al. for the ILLUMINATE Investigators Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–2122
  34. Kastelein JJP, Adkim F, Stroes ESG, Zwinderman AH, Bots ML, Stalenhoef AFH, et al. for the ENHANCE Investigators Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358:1431–1443

PII: S0939-4753(08)00230-5

doi: 10.1016/j.numecd.2008.11.003

Nutrition, Metabolism & Cardiovascular Diseases
Volume 19, Issue 8 , Pages 580-586 , October 2009

Article Tools

* Image Usage & Resolution